- Home
- RARE vs NAMS Comparison
RARE vs NAMS Comparison
Compare RARE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | NAMS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | NAMS |
|---|---|---|
| Price | $36.37 | $35.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $85.20 | $45.80 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | $35,243,000.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | 4.91 |
| 52 Week Low | $25.81 | $14.06 |
| 52 Week High | $50.00 | $42.00 |
Technical Indicators
Market Signals| Indicator | RARE | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 41.95 |
| Support Level | $33.16 | $34.52 |
| Resistance Level | $34.77 | $42.00 |
| Average True Range (ATR) | 1.52 | 2.02 |
| MACD | 0.36 | -0.66 |
| Stochastic Oscillator | 83.52 | 9.69 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.